Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01653379 · ClinicalTrials.gov registry record · Phase 2
A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism
A Phase 2 study of Secondary Hyperparathyroidism, sponsored by Deltanoid Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT01653379: Completed Phase 2 study of Secondary Hyperparathyroidism, sponsored by Deltanoid Pharmaceuticals.
NCT01653379 is a Phase 2 study of Secondary Hyperparathyroidism that has completed, run by Deltanoid Pharmaceuticals. The registered enrollment target is 42 participants, below the 60-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (30% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01653379, a Phase 2 study of Secondary Hyperparathyroidism, has completed, sponsored by Deltanoid Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, dose-ranging study of the vitamin D analog DP001 in patients with end-stage renal disease (ESRD). The primary goals of this 4-week Phase 2A study are to identify an appropriate starting dose of DP001 to be used in subsequent studies in this population and for evaluation of pharmacokinetics of DP001 in ESRD patients.
Conditions Studied
Interventions
- DRUG DP001
Study Locations (6)
Arizona
- - Tucson
California
- - Tustin
Colorado
- - Denver
Missouri
- - St Louis
Texas
- - Greenville
Wisconsin
- - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
What the finished NCT01653379 record still lists
NCT01653379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 8 other Secondary Hyperparathyroidism trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Secondary Hyperparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which DP001 is the first listed.
NCT01653379 lists 6 locations in 6 states (Arizona, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT01653379 about?
NCT01653379 is a clinical study titled "A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism". This is an open-label, dose-ranging study of the vitamin D analog DP001 in patients with end-stage renal disease (ESRD). The primary goals of this 4-week Phase 2A study are to identify an appropriate starting dose of DP001 to be used in subsequent studies in this population and for evaluation of pha...
What is the current status of trial NCT01653379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-08. Estimated completion is 2014-07.
What conditions does trial NCT01653379 study?
This clinical trial studies the following conditions: Secondary Hyperparathyroidism.
What interventions are being tested in trial NCT01653379?
The interventions under investigation include: DP001 (DRUG).
Who is sponsoring clinical trial NCT01653379?
This trial is sponsored by Deltanoid Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01653379 being conducted?
This trial has 6 study locations across Arizona, California, Colorado, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01653379's enrollment target sits among peer trials
42 6th of 8 higher than 3 of 8 other Secondary Hyperparathyroidism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Secondary Hyperparathyroidism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease
COMPLETED · Phase 2
-
Precision Medicine Approaches to Renal Osteodystrophy
RECRUITING
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
Trial to Optimize Mineral Outcomes in Dialysis Patients
COMPLETED · Phase 4
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
-
A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia